» Articles » PMID: 36216323

Does Calcified Neurocysticercosis Affect Migraine Characteristics and Treatment Responsiveness? A Case-Control Study

Overview
Specialty Tropical Medicine
Date 2022 Oct 10
PMID 36216323
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, inflammation and free-radical release has been described in the surrounding brain parenchyma of seemingly inert calcified lesions of neurocysticercosis. These free radicals can induce migraine by stimulating calcitonin gene-related peptide release. This stipulated mechanism led us to hypothesize that calcified neurocysticercosis may increase migraine severity. This case-control study included patients (migraine with calcified neurocysticercosis) and control subjects (migraine without calcified neurocysticercosis) in a 1:1 ratio. Headache frequency, visual analog scale (VAS) score, and Migraine Disability Assessment (MIDAS) score were assessed at baseline and at the end of 3 months. To compare treatment responsiveness between patients and control subjects, we treated both groups identically so that difference in treatment would not confound the results. Each group comprised 78 patients. Baseline headache frequency (11.3 ± 3.3 versus 7.9 ± 3.4), VAS score (7.5 ± 1.1 versus 6.0 ± 1.2), and MIDAS score (15 ± 7.6 versus 9.6 ± 4.5) were significantly greater in patients than control subjects. Interestingly, the change from baseline to the end of 3 months in headache frequency (6.0 ± 1.7 versus 2.8 ± 1.4), VAS score (2.6 ± 0.02 versus 1.4 ± 0.01), and MIDAS score (8.3 ± 5.0 versus 3.6 ± 2.0) were significantly greater in patients than control subjects. Our study emphasizes that calcified lesions of neurocysticercosis are not inert, and cause an increase in the frequency and severity of migraine attacks. Interestingly, these patients also showed a better response to treatment with amitriptyline, possibly resulting from its anti-inflammatory action. Further studies are warranted to explore possible inflammatory mechanisms in calcified neurocysticercosis, which influences migraine physiology.

Citing Articles

Extensive Inactive Neurocysticercosis: A Case Report in Mbeya, Southern Highlands of Tanzania.

Makasi C, Ngowi B, Stelzle D, Kilale A, Mahande M, Welte T Int Med Case Rep J. 2025; 18():117-124.

PMID: 39840234 PMC: 11748752. DOI: 10.2147/IMCRJ.S488096.

References
1.
Dejban P, Sahraei M, Chamanara M, Dehpour A, Rashidian A . Anti-inflammatory effect of amitriptyline in a rat model of acetic acid-induced colitis: the involvement of the TLR4/NF-kB signaling pathway. Fundam Clin Pharmacol. 2020; 35(5):843-851. DOI: 10.1111/fcp.12642. View

2.
Pradhan S, Das A, Anand S, Deshmukh A . Clinical characteristics of migraine in patients with calcified neurocysticercosis. Trans R Soc Trop Med Hyg. 2019; 113(7):418-423. DOI: 10.1093/trstmh/trz018. View

3.
Nash T, Pretell E, Lescano A, Bustos J, Gilman R, Gonzalez A . Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 2008; 7(12):1099-105. PMC: 3725597. DOI: 10.1016/S1474-4422(08)70243-6. View

4.
Cruz M, Cruz I, Preux P, Schantz P, Dumas M . Headache and cysticercosis in Ecuador, South America. Headache. 1995; 35(2):93-7. DOI: 10.1111/j.1526-4610.1995.hed3502093.x. View

5.
Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L . Migraine and neuropeptides. Neuropeptides. 2015; 52:19-30. DOI: 10.1016/j.npep.2015.03.006. View